Janux Therapeutics Stock Today
| JANX Stock | USD 40.72 0.11 0.27% |
Performance0 of 100
| Odds Of DistressLess than 23
|
Janux Therapeutics is trading at 40.72 as of the 18th of January 2025; that is 0.27 percent increase since the beginning of the trading day. The stock's open price was 40.61. Janux Therapeutics has about a 23 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 18th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of June 2021 | Category Healthcare | Classification Health Care |
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager platform technology to treat patients suffering from cancer. The company was incorporated in 2017 and is headquartered in La Jolla, California. The company has 58.63 M outstanding shares of which 7.68 M shares are currently shorted by private and institutional investors with about 4.79 trading days to cover. More on Janux Therapeutics
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Janux Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | David Campbell | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsJanux Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Janux Therapeutics' financial leverage. It provides some insight into what part of Janux Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Janux Therapeutics (JANX) is traded on NASDAQ Exchange in USA. It is located in 10955 Vista Sorrento Parkway, San Diego, CA, United States, 92130 and employs 76 people. Janux Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.39 B. Janux Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 58.63 M outstanding shares of which 7.68 M shares are currently shorted by private and institutional investors with about 4.79 trading days to cover.
Janux Therapeutics currently holds about 338.76 M in cash with (50.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.15.
Check Janux Therapeutics Probability Of Bankruptcy
Ownership AllocationJanux Therapeutics has a total of 58.63 Million outstanding shares. The majority of Janux Therapeutics outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Janux Therapeutics to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Janux Therapeutics. Please pay attention to any change in the institutional holdings of Janux Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Janux Ownership Details
Janux Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Cormorant Asset Management, Llc | 2024-09-30 | 1.1 M | |
| Citadel Advisors Llc | 2024-09-30 | 1 M | |
| Logos Global Management Lp | 2024-09-30 | 1000 K | |
| Lord, Abbett & Co Llc | 2024-09-30 | 703.5 K | |
| Geode Capital Management, Llc | 2024-09-30 | 662.6 K | |
| Avidity Partners Management Lp | 2024-09-30 | 562 K | |
| Vestal Point Capital Lp | 2024-09-30 | 485 K | |
| Point72 Asset Management, L.p. | 2024-09-30 | 395.9 K | |
| Goldman Sachs Group Inc | 2024-09-30 | 315.7 K | |
| Ra Capital Management, Llc | 2024-09-30 | 9.2 M | |
| Fmr Inc | 2024-09-30 | 7.8 M |
Janux Therapeutics Historical Income Statement
Janux Stock Against Markets
Janux Therapeutics Corporate Management
| Brenda Vreeswyk | Head Resources | Profile | |
| Wayne MD | Chief Officer | Profile | |
| Matt Whitmire | Vice Finance | Profile | |
| Charles Winter | Manufacturing Chemistry | Profile | |
| CFA CPA | Acting Officer | Profile | |
| Andy Meyer | Chief Officer | Profile | |
| Maria Dobek | Principal Accounting | Profile |
Additional Tools for Janux Stock Analysis
When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.